BioCentury
ARTICLE | Company News

CStone gets Chinese rights to Agios' ivosidenib

June 27, 2018 8:18 PM UTC

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies.

Agios will receive an upfront payment of $12 million and is eligible for $412 million in milestones, including $147 million in developmental and regulatory milestones and $265 million in sales milestones. About half the milestones are related to acute myelogenous leukemia (AML), cholangiocarcinoma and potential indications outside brain cancers. The remaining milestone payments are tied to brain cancer indications. Agios is also eligible for tiered, double-digit royalties. ...